President Donald Trump on Wednesday named Dr. Heidi Overton, currently a deputy director at the White House Domestic Policy Council, as his pick to lead the Food and Drug Administration — placing a close administration insider at the helm of the powerful agency.
The Nomination
Overton, a medical doctor with a doctoral degree in clinical investigation from Johns Hopkins University, has spent Trump’s second term working directly on the administration’s health policy agenda. She earned her medical degree at the University of New Mexico and, before joining the Trump White House, served as chief policy officer at the America First Policy Institute.
Trump praised the selection enthusiastically, calling Overton a smart and respected “rockstar” who would deliver faster cures, innovation, lower drug prices, and wins for Health Secretary Robert F. Kennedy Jr.’s Make America Healthy Again movement.
Overton has been a visible presence alongside Trump on health-related announcements, including his “most favored nation” drug pricing deals and an Oval Office event tied to a vaccine order that sought to separate the combined MMR vaccine into three distinct immunizations.
Filling a Vacancy Left by Makary
The nomination fills a seat that has been vacant since May, when Dr. Marty Makary stepped down as FDA commissioner. Makary departed with several significant initiatives still in progress, including work on ultraprocessed foods, antidepressant policy, and questions surrounding COVID-19 vaccine authorizations — all areas that intersect directly with the MAHA agenda.
His exit left a leadership gap at an agency central to the administration’s broader push to overhaul how the federal government evaluates food safety, pharmaceutical approvals, and public health guidance. Overton’s appointment signals that Trump intends to keep FDA policy tightly aligned with White House domestic priorities.
MAHA Priorities at the FDA
Under Kennedy’s direction, the MAHA movement has pushed the FDA toward greater scrutiny of food additives, synthetic dyes, and ultraprocessed ingredients — a significant shift from the agency’s historical posture. Makary had begun work in those areas, and Overton’s background in domestic health policy suggests the administration wants someone who can carry those efforts forward with direct knowledge of White House objectives.
Her role in the vaccine order event also indicates familiarity with some of the more contested policy questions the FDA will face, including how the agency weighs vaccine formulation decisions against public health considerations. As with all such policy positions, the administration’s claims about the benefits of splitting the MMR vaccine remain attributed to officials making them and are not settled scientific consensus.
The FDA oversees a vast regulatory portfolio that touches nearly every aspect of American food and medicine — from the approval of new drugs and medical devices to the safety standards governing what ends up on grocery store shelves. For MAHA supporters, who have called for more aggressive action on food ingredient standards and pharmaceutical transparency, Overton’s ties to the Domestic Policy Council may offer a more direct line between FDA rulemaking and White House priorities than a traditional outside appointee would provide.
What Comes Next
Overton’s nomination will require Senate confirmation before she can formally assume the role. No timeline for a confirmation hearing has been publicly announced. In the interim, the agency continues operating without a permanent confirmed commissioner, leaving ongoing projects — including those started under Makary on ultraprocessed foods and related issues — in a holding pattern.
For Idaho families and agriculture producers, the FDA’s direction on food safety standards, additive regulations, and drug pricing policy carries real consequence. Idaho’s food processing sector, dairy industry, and farm-to-consumer economy all operate within FDA-governed frameworks. A commissioner with deep MAHA alignment and direct White House experience could accelerate the kind of food system transparency and ingredient reform that many in Idaho’s agricultural and health-conscious communities have supported.
The administration’s broader health agenda — including a Trump executive order directing federal agencies to advance regenerative agriculture — reflects the same policy priorities Overton has worked on from within the Domestic Policy Council, suggesting continuity rather than a change in direction at FDA.